Atypical Presentation of a Preexisting Pancreatic Pseudocyst with Glucagon-Like Peptide-1 Agonist as a Possible Trigger for Exacerbation: A Case Report.

Pancreatitis encompasses pancreatic tissue inflammation due to enzymatic autodigestion, leading to complications such as pancreatic pseudocysts. This report details a case in which the administration of glucagon-like peptide-1 (GLP-1) agonists rendered a regressing, asymptomatic pseudocyst symptomatic. We posit that, absent other triggers, GLP-1 agonists might exacerbate pseudocysts. This emphasizes timely diagnosis and proper management. Our investigation delves into patient-specific nuances, potential mechanistic insights, the need to study this phenomenon among a broader cohort, alternative pathologies, long-term consequences, and clinical ramifications in response to a shifting pseudocyst behavior.